Sh. Sh. Abdulloeva
Sh. Sh. Abdulloeva has a total of 19 co-authors. Here are the top co-authors by number of shared publications:
- Azizzhon D. Zikiryachodzhaev
P.A. Hertzen Moscow Oncology Research Institute – branch of the National Medical Research Radiology Center, Ministry of Health of Russia
3 shared publications - Dali B. Kodzoeva
P.A. Hertsen Moscow Oncology Research Institute – branch of the National Medical Research Radiological Center, Ministry of Health of Russia
2 shared publications - Umar Kh. Khomidi
Московский научно-исследовательский онкологический институт имени П.А. Герцена – филиал ФГБУ «НМИЦ радиологии» Минздрава России
2 shared publications - Andrei Dmitrievich Kaprin
RUDN University
1 shared publication - Daria Valerievna Bagdasarova
National Medical Research Radiological Centre of the Ministry of Health of the Russian Federation, Koroleva St. 4, 249036 Obninsk, Russia
1 shared publication - Dzhamilya S. Dzhabrailova
Hertsen Moscow Oncology Research Institute – branch of the National Medical Research Radiological Centre
1 shared publication
Latest Publications
- Open Access
- 15 September 2026
- Published by Autonomous non-profit scientific and medical organization - Questions of Oncology in Voprosy onkologii
- Vol. 72 (4) , 2456
Perspectives of Omission of Axillary Lymph Node Dissection in Node-Positive Breast Cancer Patients After Neoadjuvant Chemotherapy: A Systematic Review
Введение. В данном систематическом обзоре проанализировано влияние биопсии сторожевого лимфатического узла (БСЛУ) на долгосрочные онкологические результаты у пациенток с клинически верифицированным поражением аксиллярных лимфатических узлов при раке молочной железы после неоадъювантной химиотерапии (НАПХТ) и достижение клинического ответа. Основная цель — оценить, обеспечивает ли БСЛУ при достижении клинического ответа в регионарных зонах сопоставимые показатели общей (ОВ) и безрецидивной выживаемости (БРВ) по сравнению со стандартной аксиллярной лимфодиссекцией (АЛД). Материалы и методы. Поиск литературы проведен в марте 2025 г. в базах PUBMED и Google Scholar с использованием ключевых слов breast neoplasm, node-positive, neoadjuvant chemotherapy, long-term survival, а также ручным просмотром списков ссылок включенных статей. В обзор включались рандомизированные контролируемые исследования и ретроспективные когортные исследования, оценившие отдаленные показатели ОВ, БРВ и частоту аксиллярных рецидивов в группе пациентов с клинически верифицированным поражением аксиллярных лимфатических узлов и полным клиническим регрессом после НАПХТ в зависимости от выполненного хирургического вмешательства на регионарном лимфоколлекторе. Отбор литературы и извлечение данных выполнялись двумя независимыми рецензентами по рекомендациям PRISMA с оценкой риска смещений шкалой Newcastle–Ottawa. Результаты. Из 341 найденного источника отобрано 20 исследований для систематического обзора. Пятилетняя ОВ в группах БСЛУ и АЛД составила 93,3 и 80,0 % соответственно, а БРВ — 84,7 и 73,2 % (p = 0,001). Частота аксиллярных рецидивов в обеих группах оставалась низкой и статистически не различалась (0,3–0,9 % для БСЛУ против 0,4–0,6 % для АЛД). Выводы. Объем хирургического вмешательства в регионарных зонах не показал статистически значимого влияния на отдаленные показатели выживаемости пациенток при раке молочной железы с поражением лимфатических узлов и полной клинической регрессией после НАПХТ, однако требуются результаты крупных рандомизированных исследований высокого качества с отдельным анализом подгрупп.
- 15 September 2026
- Published by Autonomous non-profit scientific and medical organization - Questions of Oncology in Voprosy onkologii
- Vol. 72 (4) , 2456
Open AccessPerspectives of Omission of Axillary Lymph Node Dissection in Node-Positive Breast Cancer Patients After Neoadjuvant Chemotherapy: A Systematic Review
Введение. В данном систематическом обзоре проанализировано влияние биопсии сторожевого лимфатического узла (БСЛУ) на долгосрочные онкологические результаты у пациенток с клинически верифицированным поражением аксиллярных лимфатических узлов при раке молочной железы после неоадъювантной химиотерапии (НАПХТ) и достижение клинического ответа. Основная цель — оценить, обеспечивает ли БСЛУ при достижении клинического ответа в регионарных зонах сопоставимые показатели общей (ОВ) и безрецидивной выживаемости (БРВ) по сравнению со стандартной аксиллярной лимфодиссекцией (АЛД). Материалы и методы. Поиск литературы проведен в марте 2025 г. в базах PUBMED и Google Scholar с использованием ключевых слов breast neoplasm, node-positive, neoadjuvant chemotherapy, long-term survival, а также ручным просмотром списков ссылок включенных статей. В обзор включались рандомизированные контролируемые исследования и ретроспективные когортные исследования, оценившие отдаленные показатели ОВ, БРВ и частоту аксиллярных рецидивов в группе пациентов с клинически верифицированным поражением аксиллярных лимфатических узлов и полным клиническим регрессом после НАПХТ в зависимости от выполненного хирургического вмешательства на регионарном лимфоколлекторе. Отбор литературы и извлечение данных выполнялись двумя независимыми рецензентами по рекомендациям PRISMA с оценкой риска смещений шкалой Newcastle–Ottawa. Результаты. Из 341 найденного источника отобрано 20 исследований для систематического обзора. Пятилетняя ОВ в группах БСЛУ и АЛД составила 93,3 и 80,0 % соответственно, а БРВ — 84,7 и 73,2 % (p = 0,001). Частота аксиллярных рецидивов в обеих группах оставалась низкой и статистически не различалась (0,3–0,9 % для БСЛУ против 0,4–0,6 % для АЛД). Выводы. Объем хирургического вмешательства в регионарных зонах не показал статистически значимого влияния на отдаленные показатели выживаемости пациенток при раке молочной железы с поражением лимфатических узлов и полной клинической регрессией после НАПХТ, однако требуются результаты крупных рандомизированных исследований высокого качества с отдельным анализом подгрупп.
- Open Access
- 4 March 2025
- Published by QUASAR, LLC in Research and Practical Medicine Journal
- Vol. 12 (1) , 8-25
Results of targeted lymphadenectomy in patients with breast cancer cT1-3N1M0 after neoadjuvant systemic therapy
Purpose of the study. To evaluate the results of targeted lymphadenectomy (TLAE) in patients with breast cancer (BC) cT1–3N1M0 after neoadjuvant systemic therapy (NAST). Patients and methods. The study represents a prospective analysis of 83 patients diagnosed with breast cancer in stage T1–3N1M0 who were treated in the Department of Reconstructive and Plastic Surgery of the breast and skin at the P. Hertsen Moscow Oncology Research Institute (Moscow, Russian Federation). The patients were divided into two groups: in the main group 1 (n = 45), TLAE was performed using a metal tag (clip) after surgery; in the control group 2 (n = 38), classical lymphadenectomy (LAE) was performed. The following characteristics were evaluated: the size of the primary tumor and its localization, the degree of malignan cy (G), the biological subtype of the tumor, the number of sentinel lymph nodes (SLN), the number of metastases in SLN, damage to other lymph nodes, the number of patients who moved from cN1 to cN0. According to these characteristics, the two groups were comparable and there were no statistically significant differences. The effectiveness of NAST was assessed by the frequency of complete pathomorphological regression of the lesion of the studied tissue. The frequency of identification of sentinel lymph nodes was assessed with urgent cytological and routine pathomorphological studies. Results. In group 1, a complete pathomorphological response in the mammary gland was 37.8 %, in group 2 – 31.6 %. A complete pathomorphological response in the affected lymph node (N0) after neoadjuvant polychemotherapy (NAST) was achieved in 51.1 % of patients in group 1 and 52.6 % in group 2. The frequency of identification of sentinel lymph nodes during biopsy in both groups was 100 %. The frequency of identification of the installed tag was 100 %. The frequency of coincidences of the clipped lymph node with the sentinel lymph node was 65 %. In one case, migration of the installed label was noted. The efficiency of using the navigation explorer was 93 %. Conclusion. The results obtained confirm the expediency, feasibility and high efficiency of de-escalation of surgical intervention in the form of TLAE. Our study also demonstrates the relative simplicity and accuracy of using a metal tag to achieve TLAE goals.
- 4 March 2025
- Published by QUASAR, LLC in Research and Practical Medicine Journal
- Vol. 12 (1) , 8-25
Open AccessResults of targeted lymphadenectomy in patients with breast cancer cT1-3N1M0 after neoadjuvant systemic therapy
Purpose of the study. To evaluate the results of targeted lymphadenectomy (TLAE) in patients with breast cancer (BC) cT1–3N1M0 after neoadjuvant systemic therapy (NAST). Patients and methods. The study represents a prospective analysis of 83 patients diagnosed with breast cancer in stage T1–3N1M0 who were treated in the Department of Reconstructive and Plastic Surgery of the breast and skin at the P. Hertsen Moscow Oncology Research Institute (Moscow, Russian Federation). The patients were divided into two groups: in the main group 1 (n = 45), TLAE was performed using a metal tag (clip) after surgery; in the control group 2 (n = 38), classical lymphadenectomy (LAE) was performed. The following characteristics were evaluated: the size of the primary tumor and its localization, the degree of malignan cy (G), the biological subtype of the tumor, the number of sentinel lymph nodes (SLN), the number of metastases in SLN, damage to other lymph nodes, the number of patients who moved from cN1 to cN0. According to these characteristics, the two groups were comparable and there were no statistically significant differences. The effectiveness of NAST was assessed by the frequency of complete pathomorphological regression of the lesion of the studied tissue. The frequency of identification of sentinel lymph nodes was assessed with urgent cytological and routine pathomorphological studies. Results. In group 1, a complete pathomorphological response in the mammary gland was 37.8 %, in group 2 – 31.6 %. A complete pathomorphological response in the affected lymph node (N0) after neoadjuvant polychemotherapy (NAST) was achieved in 51.1 % of patients in group 1 and 52.6 % in group 2. The frequency of identification of sentinel lymph nodes during biopsy in both groups was 100 %. The frequency of identification of the installed tag was 100 %. The frequency of coincidences of the clipped lymph node with the sentinel lymph node was 65 %. In one case, migration of the installed label was noted. The efficiency of using the navigation explorer was 93 %. Conclusion. The results obtained confirm the expediency, feasibility and high efficiency of de-escalation of surgical intervention in the form of TLAE. Our study also demonstrates the relative simplicity and accuracy of using a metal tag to achieve TLAE goals.
- 1 January 2024
- Published by Media Sphere Publishing Group in P.A. Herzen Journal of Oncology
- Vol. 13 (3)
Targeted lymphadenectomy with sentinel lymph node biopsy in patients with breast cancer cT1-3N1M0 after neoadjuvant polychemotherapy
Currently, in the treatment of breast cancer, there is a steady trend towards minimizing the aggressiveness of treatment and de-escalating surgical intervention, which pushes clinicians around the world to look for new dicisions. Targeted lymphadenectomy is a method of surgical intervention in areas of regional lymphatic drainage, which includes marking a clinically positive lymph node before neoadjuvant polychemotherapy with various materials (carbon tattoo, radioactive iodine, metal clamps, etc.) followed by its intraoperative removal in combination with sentinel lymph node biopsy. Undoubtedly, targeted lymphadenectomy is an innovative and effective technique designed to be the answer to the question of the optimal volume of lymphadenectomy. This review is devoted to studying the main provisions of new approaches to surgical treatment of regional areas of breast cancer, namely de-escalation of the scope of surgical treatment in areas of regional lymphatic drainage through targeted lymphadenectomy.
- 1 January 2024
- Published by Media Sphere Publishing Group in P.A. Herzen Journal of Oncology
- Vol. 13 (3)
Targeted lymphadenectomy with sentinel lymph node biopsy in patients with breast cancer cT1-3N1M0 after neoadjuvant polychemotherapy
Currently, in the treatment of breast cancer, there is a steady trend towards minimizing the aggressiveness of treatment and de-escalating surgical intervention, which pushes clinicians around the world to look for new dicisions. Targeted lymphadenectomy is a method of surgical intervention in areas of regional lymphatic drainage, which includes marking a clinically positive lymph node before neoadjuvant polychemotherapy with various materials (carbon tattoo, radioactive iodine, metal clamps, etc.) followed by its intraoperative removal in combination with sentinel lymph node biopsy. Undoubtedly, targeted lymphadenectomy is an innovative and effective technique designed to be the answer to the question of the optimal volume of lymphadenectomy. This review is devoted to studying the main provisions of new approaches to surgical treatment of regional areas of breast cancer, namely de-escalation of the scope of surgical treatment in areas of regional lymphatic drainage through targeted lymphadenectomy.